We'll always have Paris The Paris System for Reporting Urinary Cytology 2022

Eva M. Wojcik, Daniel F.I. Kurtycz, Dorothy L. Rosenthal

Research output: Contribution to journalArticlepeer-review


Following the amazing acceptance of The Paris System for Reporting Urinary Cytology (TPS), the second edition (TPS 2.0) was inevitable. Based on new studies since the publication of the first edition, diagnostic criteria are refined, and pitfalls discussed. In addition to reinforcing the mandate that the focus of diagnostic urinary cytology is the detection of high-grade urothelial carcinoma, other issues are addressed. Low-grade lesions are included in the category of negative for high-grade urothelial cancer. The rationale for that decision is strongly supported by evidence from the authors’ experiences as well as the recent literature. A new chapter on urine cytology of the upper tract, a rarely addressed topic, explores the challenges involved. Furthermore, the issue of cellular degeneration is discussed in the criteria of all diagnostic categories. Most importantly, data defining the risk of high-grade malignancy (ROHM) for each diagnostic category informs clinical management. The 65 authors are recognized authorities from 33 countries, attesting to the global impact of TPS 2.0.

Original languageEnglish (US)
Pages (from-to)62-66
Number of pages5
JournalJournal of the American Society of Cytopathology
Issue number2
StatePublished - Mar 1 2022


  • Diagnostic system
  • Malignancies of the urinary tract
  • Urinary cytology
  • Urothelial carcinoma
  • Urothelial neoplasia

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'We'll always have Paris The Paris System for Reporting Urinary Cytology 2022'. Together they form a unique fingerprint.

Cite this